Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1984-9-18
|
pubmed:abstractText |
We previously described a monoclonal antibody, 9.1C3, which blocked natural killer (NK) cell-mediated cytolysis by acting on effector cells during a late step in the lethal hit stage. The present work describes the production in rabbits of anti-idiotypic (anti-id) antibodies to the 9.1C3 antibody. In addition to reacting specifically with the 9.1C3 antibody, the anti-id antibodies bound strongly to the K562 target cell. The anti-id antibodies blocked killing of K562 targets by NK, antibody-dependent cellular cytotoxicity, and NK-like cells but did not inhibit killing by cytotoxic T lymphocytes (CTL). Pretreatment of cells and washing before assay indicated that blocking occurred at the target cell level. Of particular interest, single cell assays with Percoll-enriched large granular lymphocytes demonstrated that the antibodies caused no reduction in binding. These data are consistent with a model for NK cell-mediated lysis that involves a secondary target cell receptor independent of the primary NK-target cell interaction. The anti-id antibodies immunoprecipitated cell surface proteins of relative m.w. 79K and 62K unreduced, and 94K and 79K reduced from K562 target cells. The development of anti-id antibodies may be a useful procedure to explore the structure and function of cellular receptors involved in NK cell-mediated cytolysis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Anti-Idiotypic,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Surface,
http://linkedlifedata.com/resource/pubmed/chemical/Antilymphocyte Serum,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin Idiotypes
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0022-1767
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
133
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1385-90
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:6611373-Animals,
pubmed-meshheading:6611373-Antibodies, Anti-Idiotypic,
pubmed-meshheading:6611373-Antibodies, Monoclonal,
pubmed-meshheading:6611373-Antigen-Antibody Reactions,
pubmed-meshheading:6611373-Antigens, Surface,
pubmed-meshheading:6611373-Antilymphocyte Serum,
pubmed-meshheading:6611373-Binding, Competitive,
pubmed-meshheading:6611373-Binding Sites, Antibody,
pubmed-meshheading:6611373-Chemical Precipitation,
pubmed-meshheading:6611373-Cytotoxicity, Immunologic,
pubmed-meshheading:6611373-Humans,
pubmed-meshheading:6611373-Immunity, Cellular,
pubmed-meshheading:6611373-Immunoglobulin Idiotypes,
pubmed-meshheading:6611373-Killer Cells, Natural,
pubmed-meshheading:6611373-Rabbits
|
pubmed:year |
1984
|
pubmed:articleTitle |
Anti-idiotype antibodies to the 9.1C3 blocking antibody used to probe the lethal hit stage of NK cell-mediated cytolysis.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|